ArticleBreast cancer research and treatment2025
High PARP1 expression is associated with proliferative tumor biology in breast cancer.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPoly [ADP-ribose] polymerase (PARP) 1 enzyme is vital in DNA repair mechanisms. PARP1 inhibitors are in clinical use due to synthetic lethality in homologous-recombination repair-deficient tumors with germline BRCA1/2 mutations. Given that highly proliferative cancer requires excessive DNA replication and thus repair, we hypothesized that high PARP1 expression is associated with aggressive tumor biology in primary breast cancer regardless of subtype.
methodsThe gene expression profile of the primary breast cancer from 6351 patients from 3 independent cohorts (TCGA, METABRIC and SCAN-B) were analyzed by PARP1 expression. Transcriptomics data were analyzed in different subtypes of breast cancer separately. PARP1 high vs low expression groups was divided by the median in each cohort. PARP1 expression was also compared by response to neoadjuvant chemotherapy in 3 cohorts (GSE173839, GSE20566 and GSE20194).
resultsPARP1 expression varied significantly across breast cancer subtypes, with lower expression in hormone-receptor positive (HR +) patients. High PARP1 expression was linked to increased mutation burden, particularly in HR + tumors. It also correlated with increased activity across multiple DNA repair pathways and increased cell proliferation, with enrichment in pathways related to cell cycle. Additionally, high-PARP1 tumors exhibited greater immune cell infiltration, particularly in HR + cases. In neoadjuvant chemotherapy studies, higher PARP1 expression levels were seen in patients with pathologic complete response (pCR) rates after preoperative chemotherapy, especially in HR + subtype.
conclusionExpression of PARP1 gene is associated with aggressive cancer biology, especially in the HR + subtype of breast cancer, and may serve as a biomarker for response to chemotherapy.
Indexed as
Identifiers
41307731What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.